These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159 [TBL] [Abstract][Full Text] [Related]
44. Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. PTLD French Working Group. Caillard S; Lachat V; Moulin B Transpl Int; 2000; 13 Suppl 1():S388-93. PubMed ID: 11112039 [TBL] [Abstract][Full Text] [Related]
45. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Mentzer SJ; Perrine SP; Faller DV Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400 [TBL] [Abstract][Full Text] [Related]
46. The recipient origin of posttransplant lymphoproliferative disorders in pulmonary transplant patients. A report of three cases. Wood BL; Sabath D; Broudy VC; Raghu G Cancer; 1996 Nov; 78(10):2223-8. PubMed ID: 8918418 [TBL] [Abstract][Full Text] [Related]
47. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant. Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038 [TBL] [Abstract][Full Text] [Related]
49. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature. Ferguson NN; Thomas CP; Hohl RJ; Syrbu SI; Stone MS; Wanat KA Am J Dermatopathol; 2015 Oct; 37(10):790-4. PubMed ID: 25747810 [TBL] [Abstract][Full Text] [Related]
50. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Shahinian VB; Muirhead N; Jevnikar AM; Leckie SH; Khakhar AK; Luke PP; Rizkalla KS; Hollomby DJ; House AA Transplantation; 2003 Mar; 75(6):851-6. PubMed ID: 12660514 [TBL] [Abstract][Full Text] [Related]
51. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia. Kim JM; Lee SK; Kim SJ; Joh JW; Kwon CH; Choe YH; Shin M; Kim EY; Moon JI; Jung GO; Choi GS Transplant Proc; 2010 Apr; 42(3):895-9. PubMed ID: 20430199 [TBL] [Abstract][Full Text] [Related]
52. Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients. Ishihara M; Tanaka E; Sato T; Chikamoto H; Hisano M; Akioka Y; Dohno S; Maeda A; Hattori M; Wakiguchi H; Fujieda M Clin Nephrol; 2011 Jul; 76(1):40-8. PubMed ID: 21722604 [TBL] [Abstract][Full Text] [Related]
53. [Evaluation of PCR results in the diagnosis of Epstein-Barr virus infections]. Karadağ Geçgel S; Ersoy A; Sevinir BB; Sınırtaş M; Göral G Mikrobiyol Bul; 2012 Oct; 46(4):594-606. PubMed ID: 23188573 [TBL] [Abstract][Full Text] [Related]
54. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation. Barkholt L; Linde A; Falk KI Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864 [TBL] [Abstract][Full Text] [Related]
55. Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient. Basso S; Zecca M; Calafiore L; Rubert L; Fiocchi R; Paulli M; Quartuccio G; Guido I; Sebastiani R; Croci GA; Beschi C; Nardiello I; Ginevri F; Cugno C; Comoli P Pediatr Transplant; 2013 Nov; 17(7):E168-73. PubMed ID: 23992468 [TBL] [Abstract][Full Text] [Related]
56. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler. Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933 [TBL] [Abstract][Full Text] [Related]